A novel patient-derived organoid model for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy for screening personalized drugs.

	A novel patient-derived organoid model for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy for screening personalized drugs.
	Liu, Feiyang ; Ma, Dandan ; Liu, Qingsong ; Qi, Xiaowei
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2022-06-01
卷号	40
ISSN号	0732-183X
资助项目	Presidential Foundation of Hefei Institutes of Physical Science, Chinese Academy of Sciences, China
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000863680302526
资助机构	Presidential Foundation of Hefei Institutes of Physical Science, Chinese Academy of Sciences, China
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129813]
专题	中国科学院合肥物质科学研究院
作者单位	1.Chinese Acad Sci, Hefei Inst Phys Sci, Inst Hlth & Med Technol, Anhui Prov Key Lab Med Phys & Technol, Hefei, Peoples R China 2.Army Med Univ, Sounthwest Hosp, Dept Breast & Thyroid Surg, Chongqing, Peoples R China
推荐引用方式 GB/T 7714	Liu, Feiyang,Ma, Dandan,Liu, Qingsong,et al. A novel patient-derived organoid model for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy for screening personalized drugs.[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40.
APA	Liu, Feiyang,Ma, Dandan,Liu, Qingsong,&Qi, Xiaowei.(2022).A novel patient-derived organoid model for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy for screening personalized drugs..JOURNAL OF CLINICAL ONCOLOGY,40.
MLA	Liu, Feiyang,et al."A novel patient-derived organoid model for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy for screening personalized drugs.".JOURNAL OF CLINICAL ONCOLOGY 40(2022).